Addus HomeCare (NASDAQ:ADUS) Director Esteban Lopez Sells 250 Shares of Stock

Addus HomeCare Corporation (NASDAQ:ADUS) Director Esteban Lopez sold 250 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $93.00, for a total value of $23,250.00. Following the sale, the director owned 3,450 shares in the company, valued at $320,850. The trade was a 6.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Addus HomeCare Trading Down 0.5%

Shares of NASDAQ ADUS opened at $93.26 on Friday. The stock’s 50 day moving average price is $95.93 and its two-hundred day moving average price is $105.56. Addus HomeCare Corporation has a 52-week low of $89.76 and a 52-week high of $124.43. The stock has a market capitalization of $1.74 billion, a P/E ratio of 17.24, a PEG ratio of 1.29 and a beta of 0.92. The company has a quick ratio of 1.83, a current ratio of 1.83 and a debt-to-equity ratio of 0.08.

Addus HomeCare (NASDAQ:ADUS) last announced its quarterly earnings data on Monday, May 4th. The company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.10. Addus HomeCare had a return on equity of 9.80% and a net margin of 6.89%.The firm had revenue of $363.50 million for the quarter, compared to analysts’ expectations of $366.41 million. During the same quarter in the prior year, the firm posted $1.42 earnings per share. Addus HomeCare’s revenue for the quarter was up 7.7% compared to the same quarter last year. On average, analysts anticipate that Addus HomeCare Corporation will post 6.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Addus HomeCare

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ADUS. Capital Research Global Investors grew its holdings in Addus HomeCare by 22.3% in the 4th quarter. Capital Research Global Investors now owns 1,469,752 shares of the company’s stock worth $157,837,000 after buying an additional 268,192 shares in the last quarter. Freestone Grove Partners LP grew its holdings in Addus HomeCare by 5,035.2% in the 4th quarter. Freestone Grove Partners LP now owns 137,932 shares of the company’s stock worth $14,813,000 after buying an additional 135,246 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Addus HomeCare by 11.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 744,127 shares of the company’s stock worth $69,689,000 after buying an additional 78,415 shares in the last quarter. 8 Knots Management LLC bought a new position in Addus HomeCare in the 3rd quarter worth approximately $6,075,000. Finally, Empowered Funds LLC grew its holdings in Addus HomeCare by 186.1% in the 4th quarter. Empowered Funds LLC now owns 70,927 shares of the company’s stock worth $7,617,000 after buying an additional 46,137 shares in the last quarter. 95.35% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on ADUS shares. Wall Street Zen cut Addus HomeCare from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 21st. Barclays lowered their target price on Addus HomeCare from $102.00 to $92.00 and set an “underweight” rating for the company in a report on Friday, May 15th. KeyCorp reaffirmed an “overweight” rating on shares of Addus HomeCare in a report on Wednesday, February 25th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $139.00 target price on shares of Addus HomeCare in a report on Wednesday, February 25th. Finally, Stephens lowered their target price on Addus HomeCare from $140.00 to $135.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.22.

About Addus HomeCare

Addus HomeCare (NASDAQ: ADUS) is a leading provider of home and community-based care services for elderly, disabled, and medically complex individuals across the United States. Through a network of company-owned and franchise locations, the company delivers a broad spectrum of non-medical personal care and licensed home health services designed to support clients’ independence and quality of life.

The company’s core offerings include personal care assistance—covering daily living activities, medication reminders, and light housekeeping—and skilled home health services delivered under the supervision of registered nurses and licensed therapists.